Yasunori WatanabeLuiza MendonçaElizabeth R. AllenAndrew HoweMercede LeeJoel D. AllenHimanshi ChawlaDavid PulidoFrancesca DonnellanHannah DaviesMarta UlaszewskaSandra Belij-RammerstorferSusan MorrisAnna Sophia KrebsWanwisa DejnirattisaiJuthathip MongkolsapayaPiyada SupasaGavin R. ScreatonCatherine M. GreenTeresa LambePeijun ZhangSarah C. GilbertMax CrispinSiriraj HospitalNIHR Oxford Biomedical Research CentreDiamond Light SourceThe Wellcome Centre for Human GeneticsUniversity of OxfordUniversity of SouthamptonNuffield Department of MedicineUniversity of Oxford Medical Sciences Division2022-08-042022-08-042021-04-28ACS Central Science. Vol.7, No.4 (2021), 594-60223747951237479432-s2.0-85105109368https://repository.li.mahidol.ac.th/handle/20.500.14594/76537Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.Mahidol UniversityChemical EngineeringChemistryArticleSCOPUS10.1021/acscentsci.1c00080